Cargando…
REMDESIVIR (VEKLURY) FOR TREATING COVID-19 PATIENTS: WHAT TO EXPECT FROM A CARDIAC ELECTROPHYSIOLOGICAL PERSPECTIVE
BACKGROUND: Remdesivir was authorized with conditions in Canada on July 27, 2020 for the treatment of severe COVID-19 in adults and youth (aged ≥ 12 years) with pneumonia requiring supplemental oxygen. In the Canadian Veklury® monograph, it is mentioned that current non-clinical and clinical data do...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Published by Elsevier Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8523088/ http://dx.doi.org/10.1016/j.cjca.2021.07.093 |